Home / Europe / France / Life Sciences & Healthcare

Life Sciences & Healthcare

Our law firm – by your side to meet the challenges of today and tomorrow

Health sector companies are now facing unprecedented challenges, from pricing pressure to the growing threat from IP-infringement, digitalisation, tighter regulatory requirements imposed by the French, European and international authorities.

Against a backdrop of increased competition, you need to remain innovative and efficient. You therefore need to adapt to, and even anticipate, changes to the regulatory and operational framework. This means responding to increasingly complex questions and having access to specialist advice.

Our lawyers have particular expertise in the following areas:

  • regulatory advice and assistance (drugs, medical devices and cosmetics): legal environment surrounding clinical trials, questions relating to personal health data, advertising and promotional campaigns for healthcare products, appeals against decisions relating to marketing authorisations and reimbursements;
  • mergers & acquisitions involving health sector companies: structuring of acquisitions, divestitures and partnerships both in France and internationally, advice and support throughout all phases of the transaction (due diligence, drafting of the legal documentation, transaction implementation, etc.);
  • protection of industrial property (patents, trademarks, etc.) and confidential information: filing, monitoring, contract negotiation (R&D, licences, etc.) and related disputes (infringement actions, IP revocation actions and disputes with employee-inventors);
  • compliance: anti-corruption/FCPA, promotion best practice, declaration of interests and anti-gift regulation;
  • product liability: assistance and representation before the courts;
  • antitrust/competition: assistance with the management and definition of commercial policy, parallel imports, quotas, merger control notifications of M&A transaction in the healthcare sector, training and review of internal procedures in the event of competition investigations; compliance with rules on restrictive competition practices (invoicing, payment deadlines, etc.) and assistance in case of an inspection
  • advice and assistance in relation to sector-specific taxes and customs issues (tariff classification, customs value...).

A highly specialised team, able to adapt to all situations

In addition to the specific expertise required in relation to health, our overall understanding of the scientific, business and ethical elements that underpin your activities allows us to provide the most strategic response to each of your issues.

Our team of lawyers covers a large range of different specialisms, is widely recognised for its expertise and has a very high level of credibility both with public authorities and all sector stakeholders. We have also an extensive track record on M&A transactions in the healthcare sector (including in particular M&A in the sectors of private hospitals and healthcare facilities as well as medical biology) and we have the experience and knowledge to manage complex, international transactions as efficiently as possible. Whether you are a major international group marketing blockbusters, a small company with a very specific business activity or a biotech, we can provide you with long-term assistance with advisory and litigation services, both in France and internationally.

Choose an area

Cosmétiques
Secteur fortement compétitif, les produits cosmétiques sont soumis à une réglementation de plus en plus dense ; l&rsq
Our Tax Team
Our Employment & Pensions Team
Our Corporate/M&A Team

Feed

18/06/2024
Cannabis law and legislation in France
Medical use In principle, pursuant to Article R. 5132-86 of the French Public Health Code (PHC), the culture, manufacture, transport, import, export, holding, offer, transfer, acquisition and use of...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...
21/05/2024
Consultation of the European Commission on Vifor's commitments concerning...
In response to the Preliminary Assessment stating the potential abuse of its dominant position, Vifor proposed several commitments to rectify the potential competition law infringement. The European Commission...
16/05/2024
A broader interpretation of "substance or composition" - good news for...
A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The back­ground:Art­icle 53(c)...
08/05/2024
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicines The main rules applicable regarding advertising of medical devices were amended by (i) law n° 2011-2012...
11/04/2024
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...
25/03/2024
Patentability of inventions relating to diagnostic methods at the EPO
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...
01/01/2024
Happy new year 2024!
We wish you all the best for the New Year. In 2024, we will continue to be guided by out values: commitment, excellence, team spirit and goodwill. Watch our wishes for a happy and prosperous New Year...
18/12/2023
Digital health apps and telemedicine in France
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...